Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

Samantha Bowyer^{1

2}, Prashanth Prithviraj^{3

4}, Paul Lorigan⁵, James Larkin⁶, Grant McArthur⁷, Victoria Atkinson⁸, Michael Millward^{2

9}, Muoi Khou¹⁰, Stefan Diem⁶, Sangeetha Ramanujam¹¹, Ben Kong¹⁰, Elizabeth Liniker¹¹, Alexander Guminski¹¹, Phillip Parente¹², Miles C Andrews^{3

4}, Sagun Parakh³, Jonathan Cebon^{3

4}, Georgina V Long^{11

13}, Matteo S Carlino^{10

11

13}, Oliver Klein^{3

4}

Affiliations

¹ Rockingham General Hospital, Perth, Western Australia, Australia.
² School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia.
³ Department of Medical Oncology, Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Victoria, Australia.
⁴ Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
⁵ The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
⁶ Royal Marsden Hospital NHS Foundation Trust, London, UK.
⁷ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁸ Princess Alexandra Hospital, Greenslopes Private Hospital, Brisbane, Queensland, Australia.
⁹ Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
¹⁰ Westmead Hospital, Sydney, New South Wales, Australia.
¹¹ Melanoma Institute Australia, Sydney, New South Wales, Australia.
¹² Box Hill Hospital, Melbourne, Victoria, Australia.
¹³ University of Sydney, Sydney, New South Wales, Australia.

PMID: 28324885
PMCID: PMC5396114
DOI: 10.1038/bjc.2017.59

Comment

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

Samantha Bowyer et al. Br J Cancer. 2017.

. 2017 Apr 11;116(8):e15.

doi: 10.1038/bjc.2017.59. Epub 2017 Mar 21.

Authors

Affiliations

¹ Rockingham General Hospital, Perth, Western Australia, Australia.
² School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia.
³ Department of Medical Oncology, Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Victoria, Australia.
⁴ Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
⁵ The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
⁶ Royal Marsden Hospital NHS Foundation Trust, London, UK.
⁷ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁸ Princess Alexandra Hospital, Greenslopes Private Hospital, Brisbane, Queensland, Australia.
⁹ Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
¹⁰ Westmead Hospital, Sydney, New South Wales, Australia.
¹¹ Melanoma Institute Australia, Sydney, New South Wales, Australia.
¹² Box Hill Hospital, Melbourne, Victoria, Australia.
¹³ University of Sydney, Sydney, New South Wales, Australia.

PMID: 28324885
PMCID: PMC5396114
DOI: 10.1038/bjc.2017.59

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Comment on

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O. Bowyer S, et al. Br J Cancer. 2016 May 10;114(10):1084-9. doi: 10.1038/bjc.2016.107. Epub 2016 Apr 28. Br J Cancer. 2016. PMID: 27124339 Free PMC article.
Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.
Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Imafuku K, et al. Br J Cancer. 2017 Apr 11;116(8):e14. doi: 10.1038/bjc.2017.58. Epub 2017 Mar 21. Br J Cancer. 2017. PMID: 28324884 Free PMC article. No abstract available.

References

1. Aya F, Gaba L, Victoria I, Fernandez-Martinez A, Tosca M, Prat A, Arance A (2016) Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. Future Oncol 12(23): 2683–2688. - PubMed
1. Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O (2016) Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 114(10): 1084–1089. - PMC - PubMed
1. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19): 3167–3175. - PMC - PubMed
1. Danlos FX, Pagès C, Roux J, Jebali M, Gornet JM, Bagot M, Lebbe C (2015) Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. Melanoma Res 25: 178–179. - PubMed
1. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM (2015) Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194: 950–959. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

Affiliations

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical